Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension

Drugs & Aging
Sarah L Greig, Emma D Deeks

Abstract

Brinzolamide 1 %/brimonidine 0.2 % ophthalmic suspension (Simbrinza(®)) is a fixed-combination of a carbonic anhydrase inhibitor and an α2-adrenergic receptor agonist that is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in both the USA and EU (with the EU indication restricted to patients for whom monotherapy provides insufficient IOP reduction). In phase III randomized trials, both three-times-daily and twice-daily administration of brinzolamide/brimonidine provided significantly greater IOP-lowering efficacy over 3-6 months than either of its individual components alone, and twice-daily brinzolamide/brimonidine was noninferior to concomitant administration of brinzolamide plus brimonidine over 6 months in this regard. Brinzolamide/brimonidine was generally well tolerated, with a tolerability profile that was consistent with its individual components and with no unexpected safety findings. Therefore, brinzolamide/brimonidine is an effective treatment option for patients with open-angle glaucoma or ocular hypertension, providing a convenient alternative for those patients who require multiple IOP-lowering medications. Brinzolamide/brimonidine is t...Continue Reading

References

Dec 1, 1995·Archives of Ophthalmology·C B TorisM E Yablonski
Jan 1, 1995·Archives of Ophthalmology·J R NordlundJ Walt
Jan 1, 1997·Ophthalmology·R J DerickJ F Stoecker
Sep 11, 1999·American Journal of Ophthalmology·C B TorisM E Yablonski
Oct 8, 1999·American Journal of Ophthalmology·C J Ingram, R F Brubaker
Feb 9, 2000·Survey of Ophthalmology·L DeSantis
Mar 25, 2008·Therapeutics and Clinical Risk Management·Louis B Cantor
Feb 24, 2012·Clinical & Experimental Ophthalmology·Robert J CassonIvan Goldberg
Mar 1, 2012·Ophthalmic Epidemiology·Elizabeth E RougheadAndrew L Gilbert
Jun 28, 2012·Expert Review of Ophthalmology·Grace C Shih, David J Calkins
Feb 22, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Quang H NguyenStephen M Goode
May 16, 2014·JAMA : the Journal of the American Medical Association·Robert N WeinrebFelipe A Medeiros

❮ Previous
Next ❯

Citations

Jun 29, 2017·Expert Opinion on Drug Safety·Jed Asher Lusthaus, Ivan Goldberg
Nov 27, 2018·Pharmaceutical Development and Technology·Mohammad Mehdi MahboobianIlva Dana Rupenthal
Dec 4, 2019·Journal of Glaucoma·Nayomi PereraOliver Chen
Apr 30, 2020·Human & Experimental Toxicology·N Cimolai
Sep 6, 2019·Expert Opinion on Therapeutic Patents·Alessio Nocentini, Claudiu T Supuran
Sep 1, 2018·Vestnik oftalmologii·S Yu PetrovA V Volzhanin
Aug 27, 2021·The British Journal of Ophthalmology·Ari StonerBrent Siesky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.